Abciximab is an antiplatelet agent used to prevent blood clots during high-risk procedures. It blocks glycoprotein IIb/IIIa receptors on platelets, reducing clot formation. It is grouped under the following drug class(es): Antiplatelets, Antithrombotic agents and Monoclonal antibodies. Its therapeutic use is listed as hematologic agents. The directory classifies it as a commercial API with a peptide source/manufacturing origin. Other names for this substance include antiGPIIBIIIa, c7E3 Fab and abciximabum. Its PubChem SID is 481101467.
Abciximab
| CAS No | 143653-53-6 |
|---|---|
| Molecular Formula | N/A |
| Molecular Weight | 47,609.62 g/mol |
| Synonyms | N/A |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Abciximab is an antiplatelet agent used to prevent blood clots during high-risk procedures. It blocks glycoprotein IIb/IIIa receptors on platelets, reducing clot formation.
The listed CAS number is 143653-53-6.
The listed molecular formula is N/A.
The listed molecular weight is 47,609.62 g/mol.
N/A.
The source lists antiGPIIBIIIa, c7E3 Fab and abciximabum.